<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bacterial vaginosis: Recurrent infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bacterial vaginosis: Recurrent infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bacterial vaginosis: Recurrent infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jack D Sobel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne Marrazzo, MD, MPH, FACP, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3404474794"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bacterial vaginosis (BV) is the most common cause of abnormal vaginal discharge in reproductive-age females. Treatment is aimed at relieving symptoms, although many individuals are asymptomatic. Of those with symptoms, abnormal vaginal discharge and fishy odor are typical. Individuals with three or more documented BV episodes in one year are defined as having recurrent BV.</p><p>This topic will present the treatment options for patients with recurrent BV. Related topics on the diagnosis and initial treatment of BV, as well as the approach to the patients with vaginitis or cervicitis, are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/113103.html" rel="external">"Bacterial vaginosis: Initial treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5460.html" rel="external">"Acute cervicitis"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.</p><p class="headingAnchor" id="H4159320661"><span class="h1">DEFINITION AND POSSIBLE MECHANISMS</span><span class="headingEndMark"> — </span>Recurrent BV is defined as three or more confirmed symptomatic BV episodes in one year [<a href="#rid1">1</a>]. Patients with confirmed recurrent BV who are asymptomatic are not treated unless they are undergoing gynecologic surgery that involves the vagina. Content related to the presentation, diagnosis, and initial management of BV is presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/113103.html" rel="external">"Bacterial vaginosis: Initial treatment"</a>.)</p><p></p><p>Multiple etiologies likely contribute to the high rates of BV recurrence. Hypothesized causes include [<a href="#rid1">1-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate treatment</strong> – Medication misuse or early discontinuation may result in a persistent vaginal reservoir of organisms, particularly given that biofilm presence may be a key part of BV development and persistence [<a href="#rid6">6</a>]. A biofilm consists of a matrix of extracellular polymeric substances that often hosts microorganisms [<a href="#rid7">7</a>]; in the case of recurrent vaginal infections, the presence of <em>Gardnerella vaginalis</em> is consistent with the possibility of a biofilm reservoir for these agents. (See  <a class="medical medical_review" href="/z/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis", section on 'Pathogenesis and microbiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reinfection</strong> – Reinfection through sexual transmission from both male and female sex partners is a suspected source of recurrent BV, in part based on studies reporting reduced recurrence rates with condom use. Although this mechanism has not been directly confirmed, there are strong epidemiologic data to support it [<a href="#rid8">8-12</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Condoms or abstinence'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection relapse</strong> – Relapse despite adequate drug therapy may result from failure to eradicate the offending organisms or failure to reestablish the normal protective vaginal microbiota dominated by lactobacillus. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Impact of biofilm</strong> – Infections involving biofilms can be more difficult to eradicate [<a href="#rid6">6</a>]. This mechanism may explain the persistence of pathogenic bacteria, as documented by 16S rRNA sequencing and polymerase chain reaction (PCR) testing, in patients with documented infection who are treated with seven days of oral <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> therapy [<a href="#rid13">13</a>]. Biofilm disruption and concomitant destruction of common BV-associated bacteria (ie, <em>G. vaginalis</em>) is under investigation as a potential BV therapy and is a presumed mechanism of action for agents like boric acid [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/z/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis", section on 'Pathogenesis and microbiology'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Impact of polymicrobial infection</strong> – One study of 28 patients reported that an increase in diverse, low-abundance taxa was associated with BV recurrence after initial treatment with oral <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg twice a day for seven days total) [<a href="#rid16">16</a>]. It is not known if the bacterial diversity was an independent contributor to treatment resistance or a reflection of an established bacterial community, possibly facilitated by biofilm-forming taxa.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial resistance</strong> – While antimicrobial resistance of BV-associated bacteria might explain recurrent infection, and presence of some bacteria species have been predictive of relapse [<a href="#rid5">5,17</a>], such resistance has not been systematically studied or documented, although available evidence is sparse [<a href="#rid4">4,18</a>]. PCR and molecular techniques have identified BV pathogens that have not been successfully grown in culture, and thus the drug susceptibility and sensitivities of these organisms are not yet known [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1">Despite these limitations, patient-based studies provide evidence of progressive antimicrobial resistance:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One study of <em>G. vaginalis</em> isolates from 80 females reported progressive decrease in percentage of drug-susceptible isolates with increasing rounds of antibiotic treatment [<a href="#rid20">20</a>]. Pretreatment <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> susceptibility ranged from 88 to 100 percent and progressively decreased over four rounds of antibiotic exposure to 0 percent (percent of drug susceptible isolates: 76 to 82 percent after one round, 53 to 82 percent after second round, 36 percent after third round, and 0 percent after fourth round).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A study evaluating 41 patients with recurrent BV reported that core bacterial species did not change in abundance between vaginal specimens obtained before and after <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> treatment, which suggests drug resistance or tolerance [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> – In a study that performed quantitative vaginal cultures for 95 patients with BV, clindamycin resistance rose from 17 percent pretreatment to 53 percent posttreatment [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Limited data suggest that host characteristics, including Toll-like receptor status, might contribute to likelihood of BV and perhaps impact risk of recurrent BV; this preliminary information requires further study [<a href="#rid21">21,22</a>]. </p><p></p><p class="headingAnchor" id="H3938687531"><span class="h1">APPROACH TO TREATMENT SELECTION</span><span class="headingEndMark"> — </span>Treatment selection is driven by patient preference, medication cost and availability, and prior agents used. As trials directly comparing the extended <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> and <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a> regimens, both approaches are equally reasonable. We generally use the extended metronidazole regimen first because it is well tolerated, easy to use, and avoids the toxicity risks of vaginal boric acid  (<a class="graphic graphic_algorithm graphicRef140069" href="/z/d/graphic/140069.html" rel="external">algorithm 1</a>).</p><p>In addition, we apply the following thinking:</p><p class="bulletIndent1"><span class="glyph">●</span>When possible, we treat recurrent BV using a different drug or regimen from what was used from prior therapy given that some patients may have multiple recurrences or recur on maintenance therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there are no therapeutic options that have not yet been tried, then we use the drug and/or regimen that resulted in the best past response for the patient.</p><p></p><p class="headingAnchor" id="H1624119402"><span class="h1">TREATMENT OPTIONS</span><span class="headingEndMark"> — </span>There is no single data-driven approach to the management of recurrent BV. The approaches below are based on available supporting data and the author's experience  (<a class="graphic graphic_algorithm graphicRef140069" href="/z/d/graphic/140069.html" rel="external">algorithm 1</a>) [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H39020313"><span class="h2">Extended metronidazole regimen</span><span class="headingEndMark"> — </span>For patients with recurrent BV, we treat with a nitroimidazole followed by maintenance therapy with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> vaginal gel  (<a class="graphic graphic_algorithm graphicRef140069" href="/z/d/graphic/140069.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2154324140"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>The extended <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> regimen is generally well tolerated, easy to use, and has a lower toxicity profile compared with boric acid-containing regimens.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction</strong> – For initial treatment, we suggest treatment with oral pills or vaginal gel. The choice of initial oral pill or vaginal gel is based upon prior patient response, drug availability, and patient preferences for oral versus intravaginal therapy. In our practice, we typically use oral pills but vaginal therapy is reasonable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral pills</strong> – An oral nitroimidazole, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> or <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a> 500 mg, is given orally twice a day for seven days. </p><p></p><p class="bulletIndent2"><strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intravaginal therapy</strong> – Intravaginal <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% gel is given as a 5-gram dose twice daily for seven days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance</strong> – For maintenance therapy, we use <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% gel, 5-gram dose, placed intravaginally twice a week for four to six months [<a href="#rid1">1,24</a>]. We use maintenance therapy as prophylaxis against symptom recurrence and, in some cases, to increase chance of cure [<a href="#rid23">23</a>]. Patients who remain in remission may elect to continue maintenance therapy for a longer duration. As the optimal duration of maintenance is not known, we use shared decision-making with the patient to determine length of treatment. (See <a class="local">'Assessment of response'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent symptoms</strong> – Patients who develop BV symptoms despite maintenance therapy are again tested to confirm BV. Documented BV infection is typically a result of reinfection by a sex partner or relapse of infection. We use discuss the patient's symptoms in relation to sexual activity patterns in attempt to determine the likely cause.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reinfection by sexual contact</strong> – BV symptoms that return during or following use of maintenance therapy may be a result of reinfection by a sex partner. If reinfection from sexual activity is likely based on patient history, then patients are retreated with primary treatment and condom use is strongly encouraged. (See <a class="local">'Condoms or abstinence'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relapse of infection </strong>– Patients with confirmed recurrence that is likely relapse (ie, not reinfection from a sex partner) next try the extended <strong>vaginal</strong> boric acid regimen. (See <a class="local">'Vaginal boric acid regimen'</a> below.)</p><p></p><p class="headingAnchor" id="H3954956762"><span class="h3">Supporting data</span><span class="headingEndMark"> — </span>One multicenter prospective trial of 112 patients that compared the extended <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> gel maintenance regimen with placebo reported recurrent BV in 26 versus 59 percent of patients, respectively [<a href="#rid25">25</a>]. Secondary vaginal candidiasis was a common side effect. However, BV symptoms may return when maintenance therapy is stopped [<a href="#rid25">25,26</a>].</p><p class="headingAnchor" id="H247316867"><span class="h2">Vaginal boric acid regimen</span><span class="headingEndMark"> — </span>For this approach an oral nitroimidazole is used in combination with <strong>vaginal</strong> boric acid followed by the option of suppressive treatment with vaginal <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> gel for patients who achieve remission  (<a class="graphic graphic_algorithm graphicRef140069" href="/z/d/graphic/140069.html" rel="external">algorithm 1</a>) [<a href="#rid24">24,27-29</a>]. While solo boric acid has been used to reduce vaginal odor, it does not eradicate infection and we do not advise solo use [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H906042268"><span class="h3">Protocol</span><span class="headingEndMark"> — </span>An oral nitroimidazole is started at the same time as <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a> [<a href="#rid24">24,27,28</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction </strong>– <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> or <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>, 500 mg, orally twice daily for seven days. The oral nitroimidazole may be the same or different from the initial or most recent treatment regimen [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent1"><strong>plus</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance</strong> – Boric acid 600 mg inserted<strong> </strong>in the <strong>vagina</strong> at bedtime for a total of 30 days [<a href="#rid28">28</a>]. While the oral nitroimidazole is stopped after seven days, the <strong>vaginal</strong> boric acid is continued for 30 days of total treatment.</p><p></p><p class="bulletIndent1">Other boric acid doses and/or durations of treatment may be adequate but have not yet been studied. Boric acid should<strong> never</strong> be taken orally. (See <a class="local">'Critical warning on boric acid use'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reassessment</strong> – One to two days after finishing the <strong>vaginal </strong>boric acid, patients are evaluated for evidence of remission based on Amsel criteria or similar.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Remission</strong> – Those who achieve remission have the options of stopping treatment or continuing with maintenance therapy. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No remission</strong> – Patients who do not achieve remission are retested to confirm BV, evaluated for likely cause of infection (eg, relapse, reinfection, and/or coinfection), and treated again, preferably with a different regimen. If remission is achieved with retreatment, maintenance therapy is advised to suppress symptoms. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suppression</strong> – Patients who are in remission based on Amsel criteria or similar have the option of immediately beginning <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% gel 5 gram vaginally twice weekly for four to six months as suppressive therapy [<a href="#rid24">24,27,28</a>]. Therapy is then discontinued once treatment has been completed. Choice for suppression is based on shared decision-making with the patient. Some patients prefer to use a lower-intensity maintenance therapy rather than repeat the entire treatment regimen should BV recur.</p><p></p><p class="headingAnchor" id="H883689121"><span class="h3">Supporting data</span><span class="headingEndMark"> — </span>Six-month cure rates of 65 to 70 percent have been reported in small observational studies [<a href="#rid27">27,28</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In an observational study of 93 patients with recurrent BV treated with an oral nitroimidazole and <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a>, 99 percent (92 out of 93) were asymptomatic with ≤2 Amsel criteria at the first follow-up visit (mean 32 days) [<a href="#rid28">28</a>]. By six months from treatment, 70 percent (48 out of 69) remained in remission while 30 percent (21 out of 69) had relapsed. During the maintenance phase, five patients declined to participate, and 18 were lost to follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective chart review of 58 women treated with an oral nitroimidazole and <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a> for recurrent BV reported initial cure rates of 88 to 92 percent at 7 to 12 weeks of follow-up followed by cumulative cure rates of 87, 78, and 65 percent at 12, 16, and 28 weeks, respectively [<a href="#rid27">27</a>]. By 36 weeks of follow-up, the failure rate had risen to 50 percent.</p><p></p><p class="headingAnchor" id="H156659680"><span class="h3">Obtaining boric acid</span><span class="headingEndMark"> — </span>Boric acid vaginal suppositories use can be prescribed through a compounding pharmacy or purchased over-the-counter. Use of a compounding pharmacy may be more costly compared with over-the-counter options. Studies directly comparing these sources have not been done.</p><p class="headingAnchor" id="H1421528123"><span class="h3">Critical warning on boric acid use</span><span class="headingEndMark"> — </span><strong>Boric acid can cause death if consumed orally</strong>; patients should be told to store boric acid in a secure place that is inaccessible to children. Boric acid should not be used by individuals who are pregnant or attempting conception. Sexual partners of patients treated with <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a> have reported skin irritation after exposure [<a href="#rid30">30</a>]. The magnitude and duration of risk for skin irritation from the time of boric acid use is not known. We also counsel patients to avoid receptive oral sex while using vaginal boric acid so that their partners are not orally exposed to the drug. </p><p class="headingAnchor" id="H1398476396"><span class="h2">Risk-reducing strategies</span><span class="headingEndMark"> — </span>Adjunct approaches to reduce the risk of BV recurrence include condom use, sexual abstinence, and hormonal contraceptives. Risk of harm is low but duration of maintenance is not known. These approaches are not for primary treatment of infection.</p><p class="headingAnchor" id="H2526662288"><span class="h3">Condoms or abstinence</span><span class="headingEndMark"> — </span>Some studies have reported reduced rates of recurrence when sexual partners used condoms routinely with coitus or the patient remained abstinent [<a href="#rid3">3,31-35</a>]. For this reason, some experts suggest these behavioral interventions for those with recurrent infection. However, direct prospective trial data supporting these interventions are lacking.</p><p>In a trial studying female BV recurrence after male partner treatment with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> or placebo, condom use at the last sexual encounter (as reported by both sex partners) was associated with lower recurrence rates of BV in univariate analysis (47 versus 83 to 84 percent) [<a href="#rid36">36</a>]. The trend remained in multivariate analysis but was no longer statistically significant. Correct and consistent use of either external or internal condoms also reduces chance of pregnancy and risk of sexually transmitted infections (STIs) [<a href="#rid36">36,37</a>].</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">"External (formerly male) condoms", section on 'Protection from STIs'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">"Internal (formerly female) condoms", section on 'Sexually transmitted infections'</a>.)</p><p></p><p class="headingAnchor" id="H4114767879"><span class="h3">Hormonal contraception</span><span class="headingEndMark"> — </span>Use of hormonal contraception has been associated with reductions in BV, although most supporting data are observational [<a href="#rid38">38</a>]. Hormonal contraception may help prevent BV recurrence but is not a treatment.</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 682 women using a variety of contraceptives who underwent 16S rRNA gene analysis of vaginal fluid, those using combined estrogen-progestin oral contraceptives were 70 percent less likely to have BV-associated bacterial colonization and were nearly twice as likely to have H<sub>2</sub>O<sub>2</sub>-producing lactobacillus species compared with those using condoms [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 55 studies (mainly observational) reported that hormonal contraceptive use was associated with reduced odds of prevalent BV (pooled effect size by random effects 0.68, 95% CI 0.63-0.73) [<a href="#rid40">40</a>]. Combined estrogen-progestin and progestin-only contraceptives were associated with both reduced BV prevalence and incidence.</p><p></p><p class="headingAnchor" id="H1623729165"><span class="h3">Combination prophylactic therapy</span><span class="headingEndMark"> — </span>In a trial of Kenyan HIV-seronegative sex workers treated with either combination <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> plus <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or placebo, dosed monthly, women receiving combination treatment had fewer episodes of BV infection [<a href="#rid41">41</a>]. In a different trial of Kenyan HIV-seronegative women comparing combination treatment (metronidazole and <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a>) with placebo, treatment was associated with a reduced proportion of visits with BV over a 12-month period (21 percent in treatment group versus 32.5 percent in placebo group) [<a href="#rid42">42</a>]. In both trials, there was no impact on infection with vulvovaginal candidiasis or trichomoniasis. More trial data are needed before these therapies can be applied to a broad population.</p><p>For patients with recurrent BV, an observational study of a multidose vaginal regimen that combined high-dose <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> with <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a> reported short-term remission in 68 percent of patients [<a href="#rid43">43</a>]. This combination is not commercially available.</p><p class="headingAnchor" id="H2586563026"><span class="h1">ASSESSMENT OF RESPONSE</span><span class="headingEndMark"> — </span>We typically reevaluate patients in 4- to 16-week intervals and use a symptom-based approach to assess patient response [<a href="#rid23">23</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic</strong> – Patients who are asymptomatic at the end of suppressive therapy have the option of continuing the suppressive medication or stopping it [<a href="#rid23">23</a>]. In general, we continue the suppressive medication as patients often prefer using a lower intensity maintenance treatment rather than waiting for symptom recurrence and need for higher intensity retreatment. However, it is reasonable to stop suppressive therapy for asymptomatic individuals and observe. If BV recurs, we repeat treatment followed by a course of suppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic</strong> – Symptomatic individuals are reevaluated to confirm BV and retreated for confirmed BV recurrence. For patients who developed BV symptoms while on suppressive therapy with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> gel, we generally proceed with the triple-therapy protocol above or, for those already on the triple-phase regimen, we use extended <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a> following antibiotic treatment. </p><p></p><p class="headingAnchor" id="H2747833038"><span class="h1">INVESTIGATIONAL INTRAVAGINAL THERAPIES</span></p><p class="headingAnchor" id="H3100888274"><span class="h2">Lactobacillus crispatus</span><span class="headingEndMark"> — </span>Intravaginal treatment with <em>Lactobacillus crispatus </em>is<em> </em>a<em> </em>promising therapy to follow the initial course of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% vaginal gel for five days [<a href="#rid44">44</a>]. In a phase 2b trial comparing vaginal <em>L. crispatus </em>CTV-05 (LACTIN-V) with placebo in 228 women diagnosed with BV, patients receiving LACTIN-V had fewer BV recurrences at 12 and 24 weeks of follow-up (recurrence rate 12 weeks: 30 versus 45 percent; 24 weeks: 39 versus 54 percent) [<a href="#rid45">45</a>]. Treatment with LACTIN-V also resulted in higher rates of detectable vaginal <em>L. crispatus co</em>mpared with placebo (12 weeks: 79 versus 6 percent; 24 weeks: 48 versus 2 percent). All patients initially received seven days of vaginal metronidazole followed by 11 weeks of either therapy or placebo. Adverse event rates were similar between the two groups; no serious adverse events were attributable to either therapy. This approach is promising both for eliminating BV and for restoring <em>Lactobacillus c</em>olonization. However, limitations include that 30 percent of patients experienced recurrence during active treatment, and outcomes were not studied beyond three months. In addition, the product is not commercially available, and these results should not be extrapolated to other probiotic remedies.</p><p class="headingAnchor" id="H3695868233"><span class="h2">Boric acid with EDTA</span><span class="headingEndMark"> — </span>TOL-463 is a boric-acid based anti-infective enhanced with EDTA (ethylenediaminetetraacetic acid)<strong> </strong>that targets vaginal bacterial and fungal biofilms. In a study of 106 individuals (53 with BV, 36 with vulvovaginal candidiasis, and 17 with both infections), BV test of cure rates performed at days 9 to 12 were 59 percent for vaginal insert and 50 percent for gel [<a href="#rid15">15</a>]. Long-term follow-up was not obtained. A phase 2 study is in process [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H3737949498"><span class="h2">Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14</span><span class="headingEndMark"> — </span>Exogenous lactobacillus recolonization with 30 days of oral probiotic <em>Lactobacillus rhamnosus </em>GR-1 and <em>Lactobacillus reuteri</em> RC-14 in addition to seven days of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> therapy has been suggested, but there is minimal evidence of the efficacy of this approach [<a href="#rid47">47,48</a>]. These results should be reproduced in other trials before use of this therapy is considered.</p><p class="headingAnchor" id="H2547484048"><span class="h2">Microbiome transplant</span><span class="headingEndMark"> — </span>Vaginal microbiome transplant has been investigated in small pilot studies, without control groups, as a potential treatment for patients with recurrent BV infection [<a href="#rid49">49,50</a>]. More data are needed before this approach becomes a standard therapy.</p><p class="headingAnchor" id="H3698335798"><span class="h1">INEFFECTIVE THERAPIES</span><span class="headingEndMark"> — </span>The following treatments have not been shown to treat recurrent BV.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a><strong> for long-term suppression</strong> – While initial symptomatic relapse can be treated with a seven-day course of oral or vaginal clindamycin, long-term clindamycin regimens, oral or topical, are not advised because of toxicity (oral) and lack of documented efficacy (topical) [<a href="#rid35">35</a>]. In our experience, clindamycin therapy is frequently associated with vaginal yeast coinfections compared with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> gel. Clindamycin should not be used in women with a history of <em>C. difficile</em> infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal acidifying agents</strong> – Vaginal acidifying agents, although popular and widely used, have no role in the treatment of acute or chronic BV, as they have never been shown to enhance cure rates. Douching should be avoided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probiotics</strong> – In a randomized trial, probiotics were not more effective than placebo for prevention of relapse. (See  <a class="medical medical_review" href="/z/d/html/113103.html" rel="external">"Bacterial vaginosis: Initial treatment", section on 'Probiotics and other therapies'</a>.)</p><p></p><p class="headingAnchor" id="H3489268248"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109421.html" rel="external">"Society guideline links: Bacterial vaginosis"</a>.)</p><p class="headingAnchor" id="H1493839471"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15592.html" rel="external">"Patient education: Bacterial vaginosis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/8424.html" rel="external">"Patient education: Bacterial vaginosis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2136134889"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Recurrent bacterial vaginosis (BV) is defined as three or more confirmed symptomatic BV episodes in one year. Patients with confirmed BV who are asymptomatic do not require treatment unless they are undergoing gynecologic surgery that involves the vagina.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Definition and possible mechanisms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/113103.html" rel="external">"Bacterial vaginosis: Initial treatment", section on 'Patients who require treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – Possible mechanisms of recurrent BV include inadequate treatment, reinfection, infection relapse, and drug resistance. (See <a class="local">'Definition and possible mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to treatment selection</strong> – Treatment selection is driven by patient preferences, patient response to any prior treatments, and medication cost and availability. The approaches below are based mainly on author experience as there are limited available data. Other approaches may be acceptable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When possible, we treat recurrent BV using a different drug or regimen from what was used from prior therapy given that some patients may have multiple recurrences or recur on maintenance therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If there are no therapeutic options that have not yet been tried, then we use the drug and/or regimen that resulted in the best past response for the patient. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Otherwise, we proceed with the treatments in the order presented below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment regimens </strong>– There is no single data-driven approach to the management of recurrent BV. The approaches below are based on available supporting data and the author's experience  (<a class="graphic graphic_algorithm graphicRef140069" href="/z/d/graphic/140069.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extended </strong><strong>metronidazole</strong><strong> regimen</strong> – For patients with recurrent BV, we suggest maintenance intravaginal <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> gel after induction nitroimidazole therapy rather than induction therapy alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Induction</strong> – The choice of oral pill or vaginal gel for induction is based upon patient preferences, prior patient response, and drug availability. Patients often prefer oral to vaginal therapy but both are effective. (See <a class="local">'Extended metronidazole regimen'</a> above.)</p><p></p><p class="bulletIndent3">Oral nitroimidazole (<a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> or <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>, 500 mg) twice daily for seven days</p><p></p><p class="bulletIndent3"><strong>or</strong> </p><p></p><p class="bulletIndent3">Intravaginal <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% gel given as a 5-gram dose twice daily for seven days. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Maintenance</strong> – Maintenance therapy is started immediately after finishing induction treatment.</p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> 0.75% gel, 5-gram dose, placed vaginally twice a week for four to six months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extended </strong><strong>vaginal boric acid</strong> <strong>regimen</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Induction</strong> – For this approach, the patient starts an oral nitroimidazole and <strong>vaginal</strong> boric acid at the same time. (See <a class="local">'Protocol'</a> above.)</p><p></p><p class="bulletIndent3">Oral nitroimidazole (either <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> or <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>, 500 mg, orally twice a day).</p><p></p><p class="bulletIndent3"><strong>and </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Maintenance</strong> – <strong>Vaginal</strong> boric acid 600 mg daily (typically at night). After seven days, the nitroimidazole is stopped while the <strong>vaginal </strong>boric acid is continued for a total of 30 days. Boric acid should <strong>never</strong> be used orally. (See <a class="local">'Critical warning on boric acid use'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Suppression</strong> – Patients who achieve remission based on Amsel criteria or similar have the options of stopping treatment or immediately beginning <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 0.75% gel, 5 gram vaginally twice weekly for four to six months as suppressive therapy. The decision to start suppression is based on shared decision-making with the patient. (See <a class="local">'Protocol'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Critical warning on boric acid use</strong> – <strong>Boric acid can cause death if consumed orally. </strong>Patients should be told to store boric acid in a secure place that is inaccessible to children. Boric acid should not be used by individuals who are pregnant or attempting conception. (See <a class="local">'Critical warning on boric acid use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk-reducing strategies</strong> – Although supporting data are limited, condom use, sexual abstinence, and hormonal contraceptive use have been associated with reduced risk of BV recurrence. For all, risk of harm is low, but duration of maintenance is not known. (See <a class="local">'Risk-reducing strategies'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. Obstet Gynecol 2020; 135:e1. Reaffirmed 2022.</a></li><li><a class="nounderline abstract_t">Sobel JD, Sobel R. Current and emerging pharmacotherapy for recurrent bacterial vaginosis. Expert Opin Pharmacother 2021; 22:1593.</a></li><li><a class="nounderline abstract_t">Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193:1478.</a></li><li><a class="nounderline abstract_t">Muzny CA, Sobel JD. The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment. Antibiotics (Basel) 2022; 11.</a></li><li><a class="nounderline abstract_t">Mollin A, Katta M, Sobel JD, Akins RA. Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes. PLoS One 2022; 17:e0272012.</a></li><li><a class="nounderline abstract_t">Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 2008; 198:97.e1.</a></li><li><a class="nounderline abstract_t">Jung HS, Ehlers MM, Lombaard H, et al. Etiology of bacterial vaginosis and polymicrobial biofilm formation. Crit Rev Microbiol 2017; :1.</a></li><li><a class="nounderline abstract_t">Ratten LK, Plummer EL, Murray GL, et al. Sex is associated with the persistence of non-optimal vaginal microbiota following treatment for bacterial vaginosis: a prospective cohort study. BJOG 2021; 128:756.</a></li><li><a class="nounderline abstract_t">Sobel JD. Recurrent bacterial vaginosis, relapse or reinfection: the role of sexual transmission. BJOG 2021; 128:768.</a></li><li><a class="nounderline abstract_t">Muzny CA, Schwebke JR. Gardnerella vaginalis: Still a Prime Suspect in the Pathogenesis of Bacterial Vaginosis. Curr Infect Dis Rep 2013; 15:130.</a></li><li><a class="nounderline abstract_t">Forcey DS, Vodstrcil LA, Hocking JS, et al. Factors Associated with Bacterial Vaginosis among Women Who Have Sex with Women: A Systematic Review. PLoS One 2015; 10:e0141905.</a></li><li><a class="nounderline abstract_t">Swidsinski A, Doerffel Y, Loening-Baucke V, et al. Gardnerella biofilm involves females and males and is transmitted sexually. Gynecol Obstet Invest 2010; 70:256.</a></li><li><a class="nounderline abstract_t">Verwijs MC, Agaba SK, Darby AC, van de Wijgert JHHM. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. Am J Obstet Gynecol 2020; 222:157.e1.</a></li><li><a class="nounderline abstract_t">Landlinger C, Tisakova L, Oberbauer V, et al. Engineered Phage Endolysin Eliminates Gardnerella Biofilm without Damaging Beneficial Bacteria in Bacterial Vaginosis Ex Vivo. Pathogens 2021; 10.</a></li><li><a class="nounderline abstract_t">Marrazzo JM, Dombrowski JC, Wierzbicki MR, et al. Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. Clin Infect Dis 2019; 68:803.</a></li><li><a class="nounderline abstract_t">Gustin AT, Thurman AR, Chandra N, et al. Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis. Am J Obstet Gynecol 2022; 226:225.e1.</a></li><li><a class="nounderline abstract_t">Marrazzo JM, Thomas KK, Fiedler TL, et al. Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med 2008; 149:20.</a></li><li><a class="nounderline abstract_t">Beigi RH, Austin MN, Meyn LA, et al. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004; 191:1124.</a></li><li><a class="nounderline abstract_t">Javed A, Parvaiz F, Manzoor S. Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and it's associated resistance patterns. Microb Pathog 2019; 127:21.</a></li><li><a class="nounderline abstract_t">Bannatyne RM, Smith AM. Recurrent bacterial vaginosis and metronidazole resistance in Gardnerella vaginalis. Sex Transm Infect 1998; 74:455.</a></li><li><a class="nounderline abstract_t">Dela Cruz EJ, Fiedler TL, Liu C, et al. Genetic Variation in Toll-Like Receptor 5 and Colonization with Flagellated Bacterial Vaginosis-Associated Bacteria. Infect Immun 2021; 89.</a></li><li><a class="nounderline abstract_t">Murphy K, Mitchell CM. The Interplay of Host Immunity, Environment and the Risk of Bacterial Vaginosis and Associated Reproductive Health Outcomes. J Infect Dis 2016; 214 Suppl 1:S29.</a></li><li class="breakAll">Sobel J, Wayne State University School of Medicine, 2023, personal communication.</li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006; 194:1283.</a></li><li><a class="nounderline abstract_t">Aguin T, Akins RA, Sobel JD. High-dose vaginal maintenance metronidazole for recurrent bacterial vaginosis: a pilot study. Sex Transm Dis 2014; 41:290.</a></li><li><a class="nounderline abstract_t">Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009; 36:732.</a></li><li><a class="nounderline abstract_t">Surapaneni S, Akins R, Sobel JD. Recurrent Bacterial Vaginosis: An Unmet Therapeutic Challenge. Experience With a Combination Pharmacotherapy Long-Term Suppressive Regimen. Sex Transm Dis 2021; 48:761.</a></li><li><a class="nounderline abstract_t">Powell A, Ghanem KG, Rogers L, et al. Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis. Sex Transm Dis 2019; 46:810.</a></li><li class="breakAll">Barbieri R, Harvard Medical School, Harvard University, 2021, personal communication.</li><li><a class="nounderline abstract_t">Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 2007; 44:213.</a></li><li><a class="nounderline abstract_t">Sanchez S, Garcia PJ, Thomas KK, et al. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol 2004; 191:1898.</a></li><li><a class="nounderline abstract_t">Schwebke JR, Desmond R. Risk factors for bacterial vaginosis in women at high risk for sexually transmitted diseases. Sex Transm Dis 2005; 32:654.</a></li><li><a class="nounderline abstract_t">Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect 2004; 80:58.</a></li><li><a class="nounderline abstract_t">Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013; 56:777.</a></li><li><a class="nounderline abstract_t">Schwebke JR, Lensing SY, Lee J, et al. Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis 2021; 73:e672.</a></li><li><a class="nounderline abstract_t">Beksinska M, Wong R, Smit J. Male and female condoms: Their key role in pregnancy and STI/HIV prevention. Best Pract Res Clin Obstet Gynaecol 2020; 66:55.</a></li><li><a class="nounderline abstract_t">Davis A, Crawley A, Ashmore M, et al. Sociodemographic and Behavioral Predictors of Recurrent Bacterial Vaginosis Among Sexual Health Clinic Patients in New York City From 2014 to 2018. Sex Transm Dis 2023; 50:645.</a></li><li><a class="nounderline abstract_t">Brooks JP, Edwards DJ, Blithe DL, et al. Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome. Contraception 2017; 95:405.</a></li><li><a class="nounderline abstract_t">Vodstrcil LA, Hocking JS, Law M, et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One 2013; 8:e73055.</a></li><li><a class="nounderline abstract_t">McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis 2008; 197:1361.</a></li><li><a class="nounderline abstract_t">McClelland RS, Balkus JE, Lee J, et al. Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women. J Infect Dis 2015; 211:1875.</a></li><li><a class="nounderline abstract_t">Sobel JD, Kaur N, Woznicki NA, et al. Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses. Infect Drug Resist 2019; 12:2297.</a></li><li><a class="nounderline abstract_t">Lagenaur LA, Hemmerling A, Chiu C, et al. Connecting the Dots: Translating the Vaginal Microbiome Into a Drug. J Infect Dis 2021; 223:S296.</a></li><li><a class="nounderline abstract_t">Cohen CR, Wierzbicki MR, French AL, et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med 2020; 382:1906.</a></li><li class="breakAll">TOL-463 Phase 2 Study for Vaginitis. ClinicalTrials.gov identifier: NCT02866227. US National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT02866227 (Accessed on October 27, 2021).</li><li><a class="nounderline abstract_t">Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev 2009; :CD006055.</a></li><li><a class="nounderline abstract_t">Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 2006; 8:1450.</a></li><li><a class="nounderline abstract_t">Ma D, Chen Y, Chen T. Vaginal microbiota transplantation for the treatment of bacterial vaginosis: a conceptual analysis. FEMS Microbiol Lett 2019; 366.</a></li><li><a class="nounderline abstract_t">Lev-Sagie A, Goldman-Wohl D, Cohen Y, et al. Vaginal microbiome transplantation in women with intractable bacterial vaginosis. Nat Med 2019; 25:1500.</a></li></ol></div><div id="topicVersionRevision">Topic 131928 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31856123" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33750246" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Current and emerging pharmacotherapy for recurrent bacterial vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16652274" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35453251" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35901180" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18005928" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28358585" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Etiology of bacterial vaginosis and polymicrobial biofilm formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33480468" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Sex is associated with the persistence of non-optimal vaginal microbiota following treatment for bacterial vaginosis: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33241645" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recurrent bacterial vaginosis, relapse or reinfection: the role of sexual transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23371405" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gardnerella vaginalis: Still a Prime Suspect in the Pathogenesis of Bacterial Vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26675816" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Factors Associated with Bacterial Vaginosis among Women Who Have Sex with Women: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051845" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gardnerella biofilm involves females and males and is transmitted sexually.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31404542" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33435575" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Engineered Phage Endolysin Eliminates Gardnerella Biofilm without Damaging Beneficial Bacteria in Bacterial Vaginosis Ex Vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30184181" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34560047" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591634" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507930" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antimicrobial resistance associated with the treatment of bacterial vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30502515" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and it's associated resistance patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10195061" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recurrent bacterial vaginosis and metronidazole resistance in Gardnerella vaginalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33199356" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Genetic Variation in Toll-Like Receptor 5 and Colonization with Flagellated Bacterial Vaginosis-Associated Bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27056955" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The Interplay of Host Immunity, Environment and the Risk of Bacterial Vaginosis and Associated Reproductive Health Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27056955" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Interplay of Host Immunity, Environment and the Risk of Bacterial Vaginosis and Associated Reproductive Health Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16647911" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24722380" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : High-dose vaginal maintenance metronidazole for recurrent bacterial vaginosis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704395" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34110746" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Recurrent Bacterial Vaginosis: An Unmet Therapeutic Challenge. Experience With a Combination Pharmacotherapy Long-Term Suppressive Regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31663976" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31663976" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17173219" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592270" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254538" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk factors for bacterial vaginosis in women at high risk for sexually transmitted diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14755039" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Social and sexual risk factors for bacterial vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23243173" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33383580" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32007451" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Male and female condoms: Their key role in pregnancy and STI/HIV prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37432999" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sociodemographic and Behavioral Predictors of Recurrent Bacterial Vaginosis Among Sexual Health Clinic Patients in New York City From 2014 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913230" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24023807" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444793" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25526757" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Randomized Trial of Periodic Presumptive Treatment With High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31413606" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33330916" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Connecting the Dots: Translating the Vaginal Microbiome Into a Drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32402161" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32402161" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588379" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16697231" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30715301" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vaginal microbiota transplantation for the treatment of bacterial vaginosis: a conceptual analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31591599" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vaginal microbiome transplantation in women with intractable bacterial vaginosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
